Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2017 May;15(5):563-573.

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Author information

1
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2
Memorial Sloan Kettering Cancer Center
3
University of Wisconsin Carbone Cancer Center
4
Dana-Farber/Brigham and Women’s Cancer Center
5
Mayo Clinic Cancer Center
6
Moffitt Cancer Center
7
Fred & Pamela Buffett Cancer Center
8
Vanderbilt-Ingram Cancer Center
9
Stanford Cancer Institute
10
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
11
Roswell Park Cancer Institute
12
University of Alabama at Birmingham Comprehensive Cancer Center
13
Fox Chase Cancer Center
14
UCSF Helen Diller Family Comprehensive Cancer Center
15
Huntsman Cancer Institute at the University of Utah
16
Duke Cancer Institute
17
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
18
University of Michigan Comprehensive Cancer Center
19
University of Colorado Cancer Center
20
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
21
UC San Diego Moores Cancer Center
22
City of Hope Comprehensive Cancer Center
23
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
24
Yale Cancer Center/Smilow Cancer Hospital
25
St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
26
The University of Texas MD Anderson Cancer Center
27
Massachusetts General Hospital Cancer Center
28
National Comprehensive Cancer Network

Abstract

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.

PMID:
28476736
PMCID:
PMC5557008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center